Michael A. Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael A. Gonzalez has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Stephan Züchner
Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA
3 shared publications - Ahmad Abou Tayoun
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates
2 shared publications - Anthony Antonellis
Department of Human Genetics University of Michigan Medical School Ann Arbor Michigan USA
2 shared publications - Laurie Beth Griffin
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Warren Alpert Medical School at Brown University, Providence, RI
2 shared publications - Mahdi Sarmady
Children's Hospital of Philadelphia, University of Pennsylvania
2 shared publications Perry Evans
Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
2 shared publications
Latest Publications
- 9 January 2019
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 27 (4) , 612-620
Rapid and accurate interpretation of clinical exomes using Phenoxome: a computational phenotype-driven approach
Clinical exome sequencing (CES) has become the preferred diagnostic platform for complex pediatric disorders with suspected monogenic etiologies. Despite rapid advancements, the major challenge still resides in identifying the casual variants among the thousands of variants detected during CES testing, and thus establishing a molecular diagnosis. To improve the clinical exome diagnostic efficiency, we developed Phenoxome, a robust phenotype-driven model that adopts a network-based approach to facilitate automated variant prioritization. Phenoxome dissects the phenotypic manifestation of a patient in concert with their genomic profile to filter and then prioritize variants that are likely to affect the function of the gene (potentially pathogenic variants). To validate our method, we have compiled a clinical cohort of 105 positive patient samples that represent a wide range of genetic heterogeneity. Phenoxome identifies the causative variants within the top 5, 10, or 25 candidates in more than 50%, 71%, or 88% of these exomes, respectively. Furthermore, we show that our method is optimized for clinical testing by outperforming the current state-of-art method. We have demonstrated the performance of Phenoxome using a clinical cohort and showed that it enables rapid and accurate interpretation of clinical exomes. Phenoxome is available at https://phenoxome.chop.edu/.
- 9 January 2019
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 27 (4) , 612-620
Rapid and accurate interpretation of clinical exomes using Phenoxome: a computational phenotype-driven approach
Clinical exome sequencing (CES) has become the preferred diagnostic platform for complex pediatric disorders with suspected monogenic etiologies. Despite rapid advancements, the major challenge still resides in identifying the casual variants among the thousands of variants detected during CES testing, and thus establishing a molecular diagnosis. To improve the clinical exome diagnostic efficiency, we developed Phenoxome, a robust phenotype-driven model that adopts a network-based approach to facilitate automated variant prioritization. Phenoxome dissects the phenotypic manifestation of a patient in concert with their genomic profile to filter and then prioritize variants that are likely to affect the function of the gene (potentially pathogenic variants). To validate our method, we have compiled a clinical cohort of 105 positive patient samples that represent a wide range of genetic heterogeneity. Phenoxome identifies the causative variants within the top 5, 10, or 25 candidates in more than 50%, 71%, or 88% of these exomes, respectively. Furthermore, we show that our method is optimized for clinical testing by outperforming the current state-of-art method. We have demonstrated the performance of Phenoxome using a clinical cohort and showed that it enables rapid and accurate interpretation of clinical exomes. Phenoxome is available at https://phenoxome.chop.edu/.
- 21 June 2018
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 20 (5) , 643-652
The Development and Validation of Clinical Exome-Based Panels Using ExomeSlicer
- 21 June 2018
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 20 (5) , 643-652
The Development and Validation of Clinical Exome-Based Panels Using ExomeSlicer
- 14 September 2015
- Published by Elsevier in Mitochondrion
- Vol. 24, S16
An Ugo1-like protein is associated with optic atrophy ‘plus’ disorders
- 14 September 2015
- Published by Elsevier in Mitochondrion
- Vol. 24, S16
An Ugo1-like protein is associated with optic atrophy ‘plus’ disorders
- 1 October 2014
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 95 (4) , 472
Synaptotagmin 2 Mutations Cause an Autosomal-Dominant Form of Lambert-Eaton Myasthenic Syndrome and Nonprogressive Motor Neuropathy
- 1 October 2014
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 95 (4) , 472
Synaptotagmin 2 Mutations Cause an Autosomal-Dominant Form of Lambert-Eaton Myasthenic Syndrome and Nonprogressive Motor Neuropathy
- Open Access
- 28 August 2014
- Published by Wiley in Human Mutation
- Vol. 35 (11) , 1363-1371
Impaired Function is a Common Feature of Neuropathy-Associated Glycyl-tRNA Synthetase Mutations
C harcot–M arie–T ooth disease type 2D (CMT 2D ) is an autosomal‐dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl‐tRNA synthetase (GARS ) gene cause CMT 2D . GARS is a member of the ubiquitously expressed aminoacyl‐tRNA synthetase (ARS ) family and is responsible for charging tRNA with glycine. To date, 13 GARS mutations have been identified in patients with CMT disease. While functional studies have revealed loss‐of‐function characteristics, only four GARS mutations have been rigorously studied. Here, we report the functional evaluation of nine CMT ‐associated GARS mutations in tRNA charging, yeast complementation, and subcellular localization assays. Our results demonstrate that impaired function is a common characteristic of CMT ‐associated GARS mutations. Additionally, one mutation previously associated with CMT disease (p.S er581L eu) does not demonstrate impaired function, was identified in the general population, and failed to segregate with disease in two newly identified families with CMT disease. Thus, we propose that this variant is not a disease‐causing mutation. Together, our data indicate that impaired function is a key component of GARS ‐mediated CMT disease and emphasize the need for careful genetic and functional evaluation before implicating a variant in disease onset.
- 28 August 2014
- Published by Wiley in Human Mutation
- Vol. 35 (11) , 1363-1371
Open AccessImpaired Function is a Common Feature of Neuropathy-Associated Glycyl-tRNA Synthetase Mutations
C harcot–M arie–T ooth disease type 2D (CMT 2D ) is an autosomal‐dominant axonal peripheral neuropathy characterized by impaired motor and sensory function in the distal extremities. Mutations in the glycyl‐tRNA synthetase (GARS ) gene cause CMT 2D . GARS is a member of the ubiquitously expressed aminoacyl‐tRNA synthetase (ARS ) family and is responsible for charging tRNA with glycine. To date, 13 GARS mutations have been identified in patients with CMT disease. While functional studies have revealed loss‐of‐function characteristics, only four GARS mutations have been rigorously studied. Here, we report the functional evaluation of nine CMT ‐associated GARS mutations in tRNA charging, yeast complementation, and subcellular localization assays. Our results demonstrate that impaired function is a common characteristic of CMT ‐associated GARS mutations. Additionally, one mutation previously associated with CMT disease (p.S er581L eu) does not demonstrate impaired function, was identified in the general population, and failed to segregate with disease in two newly identified families with CMT disease. Thus, we propose that this variant is not a disease‐causing mutation. Together, our data indicate that impaired function is a key component of GARS ‐mediated CMT disease and emphasize the need for careful genetic and functional evaluation before implicating a variant in disease onset.